NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6200.00 88.00 (1.44%)

25.13% Gain from 52W Low

745.2K NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

164,590.5

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Search Inside the pdf :

Divi's Laboratories Ltd.

29 Aug 2025

6200.00

1.44%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Divi's Laboratories Ltd. is trading below its 50 day SMA of 6303.9

Divi's Laboratories Ltd.

07 Aug 2025

6200.00

1.44%

Divi's Laboratories (DIVI IN) Q1FY26 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q1FY26 EBITDA was 4% below our estimates led by lower margins despite higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates stand marginally reduced by 3-4%. We expect 20% EBITDA CAGR and 12% PAT CAGR over FY25-27E. At CMP,...

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

19 May 2025, 12:00AM

6200.00

1.44%

Divi's Laboratories (DIVI IN) Q4FY25 Result Update Margin...

Accumulate: Divi's Laboratories Ltd.

Target

Prabhudas Lilladhar

Divi's Laboratories (DIVI) Q4FY25 EBITDA beat our estimates led by higher gross margin (62%; up 200 bps QoQ). We expect GMs to sustain, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP's and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged. We expect 22% EBITDA CAGR and 15% PAT CAGR over FY25-27E. At CMP, stock is trading at...

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

25 Mar 2025

6200.00

1.44%

DIVI' S LAB

Hold: Divi's Laboratories Ltd.

Target

Geojit BNP Paribas

Divi's Laboratories Ltd. is trading above its 200 day SMA of 6120.8

Divi's Laboratories Ltd.

04 Feb 2025

6200.00

1.44%